LA JOLLA PHARMACEUTICAL CO Uncategorized Contracts & Agreements

88 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Support Agreement, dated as of July 10, 2022, by and among the Parent, the Purchaser and the stockholders named therein
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2022
Description of Securities
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2022
Amendment, dated as of December 5, 2017, by and between the Registrant and the President and Fellows of Harvard College, as amended
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2021
PAION AG Exclusive Licensing Agreement, dated January 12, 2021
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2021
Form of Contingent Value Rights Agreement, by and between La Jolla and the Rights Agent
LA JOLLA PHARMACEUTICAL CO
Biotechnology
DE
2020
Description of Securities
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2020
Revenue Interest Agreement, dated May 10, 2018, among La Jolla Pharma, LLC, HealthCare Royalty Partners III, L.P., HCRP Overflow Fund, L.P. and HCR Molag Fund, L.P
LA JOLLA PHARMACEUTICAL CO
Biotechnology
NY
2018
Dated:March 16, 2015/s/ Dennis M. MulroyDennis M. Mulroy
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2015
LA JOLLA PHARMACEUTICAL COMPANY
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2012
CONSENT AND AMENDMENT AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2012
SECOND AMENDMENT AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2011
AMENDMENT AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2011
CONSENT AND AMENDMENT AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2011
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2010
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2009
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Sell or out-license our remaining assets, including our SSAO compounds, although we do not expect to receive any substantive value for them
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
AMENDMENT NO. 1 TO AMENDED AND RESTATED RIGHTS AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2009
Entry into a Material Definitive Agreement
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2008
Entry into a Material Definitive Agreement
LA JOLLA PHARMACEUTICAL CO
Biotechnology
NY
2008
Entry into a Material Definitive Agreement
LA JOLLA PHARMACEUTICAL CO
Biotechnology
NY
2008
* * *
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2008
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2007
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2007
Focus on higher doses all new patients entering the study will be randomized in equal numbers to receive weekly doses of either 300 mg or 900 mg of Riquent or placebo, with no...
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2007
Focus on higher doses all new patients entering the study will be randomized in equal numbers to receive weekly doses of either 300 mg or 900 mg of Riquent or placebo, with no...
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2007
Current assets
LA JOLLA PHARMACEUTICAL CO
Biotechnology
CA
2006
/s/ Michael Tansey 7/14/06 Michael Tansey, BSc, MB ChB, MD, FFPM Date
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2006
AMENDMENT NO. 3 TO RIGHTS AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2006
AMENDMENT NO. 2 TO RIGHTS AGREEMENT
LA JOLLA PHARMACEUTICAL CO
Biotechnology
2005